Table 4. Selected adverse events.
| Selected AEs, n (%) | ERIVANCE BCC (N = 104) | EAS (N = 119) | ||
|---|---|---|---|---|
| ≥65 years (n = 47) |
<65 years (n = 57) |
≥65 years (n = 53) |
<65 years (n = 66) |
|
| Any AE | 47 (100) | 57 (100) | 52 (98) | 64 (97) |
| Grade 3-5 AE | 24 (51) | 20 (35) | 13 (25) | 14 (21) |
| AE leading to discontinuation | 7 (15) | 6 (11) | 6 (11) | 1 (2) |
| Muscle spasms | 30 (64) | 41 (72) | 37 (70) | 47 (73) |
| Dysgeusia | 24 (51) | 29 (51) | 37 (70) | 47 (73) |
| Alopecia | 23 (49) | 43 (75) | 29 (55) | 40 (61) |
| Nausea | 12 (25) | 18 (32) | 9 (17) | 14 (21) |
| Diarrhea | 8 (17) | 15 (26) | 14 (26) | 16 (24) |
| Ageusia | 7 (15) | 5 (9) | 2 (4) | 1 (2) |
| Constipation | 11 (23) | 6 (11) | 5 (9) | 9 (14) |
| Arthralgia | 6 (13) | 10 (18) | 0 | 4 (6) |
| Decreased weight | 23 (49) | 25 (44) | 10 (19) | 9 (14) |
| Decreased appetite | 14 (30) | 10 (18) | 7 (13) | 9 (14) |
| Fatigue | 17 (36) | 20 (35) | 10 (19) | 13 (20) |
AE = adverse event; BCCNS = basal cell carcinoma nevus syndrome; EAS = expanded access study.